Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus

Atsuhiro Ichihara, Matsuhiko Hayashi, Munekazu Ryuzaki, Michiko Handa, Tomohiro Furukawa, Takao Saruta

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Background. Arterial stiffness assessed by pulse wave velocity (PWV) predicts all-cause and cardiovascular mortality in diabetic patients with end-stage renal disease. We studied the preventive effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on arterial PWV values in this population. Methods. Twenty-two patients with normal serum lipid levels received fluvastatin (20 mg/day p.o.) or a placebo for 6 months. Their serum lipid levels, serum levels of C-reactive protein (CRP), arterial PWV, and ankle branchial indexes (ABI) were determined before, and 3 and 6 months after taking the medication to evaluate arterial stiffness. Results. At the beginning of the follow-up, there were no differences in age, blood pressure, body mass index, serum haemoglobin A1c level, serum CRP level, serum lipid levels, PWV or ABI between the placebo- (n = 10) and the fluvastatin-treated patients (n = 12). After 6 months, the PWV and the serum oxidized low-density lipoprotein cholesterol (LDL-C) level increased significantly (from 1969 ± 140 to 2326 ± 190 cm/s and 70.4 ± 13.8 to 91.8 ± 15.5 U/l, respectively) in the placebo-treated patients. However, the fluvastatin group had a significantly reduced PWV (from 1991 ± 162 to 1709 ± 134 cm/s), oxidized LDL-C serum levels (from 89.0 ± 9.6 to 73.0 ± 5.8 U/l) and CRP serum levels (from 0.97 ± 0.32 to 0.26 ± 0.16 mg/dl) compared with those in the placebo group. Conclusions. Long-term administration of fluvastatin prevents further worsening of arterial biomechanics in haemodialysis patients with type 2 diabetes mellitus, even in the presence of serum lipid levels in the normal range.

Original languageEnglish
Pages (from-to)1513-1517
Number of pages5
JournalNephrology Dialysis Transplantation
Volume17
Issue number8
Publication statusPublished - 2002

Fingerprint

fluvastatin
Vascular Stiffness
Type 2 Diabetes Mellitus
Renal Dialysis
Pulse Wave Analysis
Serum
Placebos
C-Reactive Protein
Lipids
Ankle
LDL Cholesterol

Keywords

  • Ankle brachial index
  • End-stage renal disease
  • HMG-CoA reductase inhibitor
  • Oxidized low-density lipoprotein
  • Pulse wave velocity

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Ichihara, A., Hayashi, M., Ryuzaki, M., Handa, M., Furukawa, T., & Saruta, T. (2002). Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrology Dialysis Transplantation, 17(8), 1513-1517.

Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. / Ichihara, Atsuhiro; Hayashi, Matsuhiko; Ryuzaki, Munekazu; Handa, Michiko; Furukawa, Tomohiro; Saruta, Takao.

In: Nephrology Dialysis Transplantation, Vol. 17, No. 8, 2002, p. 1513-1517.

Research output: Contribution to journalArticle

Ichihara, A, Hayashi, M, Ryuzaki, M, Handa, M, Furukawa, T & Saruta, T 2002, 'Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus', Nephrology Dialysis Transplantation, vol. 17, no. 8, pp. 1513-1517.
Ichihara, Atsuhiro ; Hayashi, Matsuhiko ; Ryuzaki, Munekazu ; Handa, Michiko ; Furukawa, Tomohiro ; Saruta, Takao. / Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. In: Nephrology Dialysis Transplantation. 2002 ; Vol. 17, No. 8. pp. 1513-1517.
@article{b829890e818143e697d489cdebb2110c,
title = "Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus",
abstract = "Background. Arterial stiffness assessed by pulse wave velocity (PWV) predicts all-cause and cardiovascular mortality in diabetic patients with end-stage renal disease. We studied the preventive effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on arterial PWV values in this population. Methods. Twenty-two patients with normal serum lipid levels received fluvastatin (20 mg/day p.o.) or a placebo for 6 months. Their serum lipid levels, serum levels of C-reactive protein (CRP), arterial PWV, and ankle branchial indexes (ABI) were determined before, and 3 and 6 months after taking the medication to evaluate arterial stiffness. Results. At the beginning of the follow-up, there were no differences in age, blood pressure, body mass index, serum haemoglobin A1c level, serum CRP level, serum lipid levels, PWV or ABI between the placebo- (n = 10) and the fluvastatin-treated patients (n = 12). After 6 months, the PWV and the serum oxidized low-density lipoprotein cholesterol (LDL-C) level increased significantly (from 1969 ± 140 to 2326 ± 190 cm/s and 70.4 ± 13.8 to 91.8 ± 15.5 U/l, respectively) in the placebo-treated patients. However, the fluvastatin group had a significantly reduced PWV (from 1991 ± 162 to 1709 ± 134 cm/s), oxidized LDL-C serum levels (from 89.0 ± 9.6 to 73.0 ± 5.8 U/l) and CRP serum levels (from 0.97 ± 0.32 to 0.26 ± 0.16 mg/dl) compared with those in the placebo group. Conclusions. Long-term administration of fluvastatin prevents further worsening of arterial biomechanics in haemodialysis patients with type 2 diabetes mellitus, even in the presence of serum lipid levels in the normal range.",
keywords = "Ankle brachial index, End-stage renal disease, HMG-CoA reductase inhibitor, Oxidized low-density lipoprotein, Pulse wave velocity",
author = "Atsuhiro Ichihara and Matsuhiko Hayashi and Munekazu Ryuzaki and Michiko Handa and Tomohiro Furukawa and Takao Saruta",
year = "2002",
language = "English",
volume = "17",
pages = "1513--1517",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus

AU - Ichihara, Atsuhiro

AU - Hayashi, Matsuhiko

AU - Ryuzaki, Munekazu

AU - Handa, Michiko

AU - Furukawa, Tomohiro

AU - Saruta, Takao

PY - 2002

Y1 - 2002

N2 - Background. Arterial stiffness assessed by pulse wave velocity (PWV) predicts all-cause and cardiovascular mortality in diabetic patients with end-stage renal disease. We studied the preventive effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on arterial PWV values in this population. Methods. Twenty-two patients with normal serum lipid levels received fluvastatin (20 mg/day p.o.) or a placebo for 6 months. Their serum lipid levels, serum levels of C-reactive protein (CRP), arterial PWV, and ankle branchial indexes (ABI) were determined before, and 3 and 6 months after taking the medication to evaluate arterial stiffness. Results. At the beginning of the follow-up, there were no differences in age, blood pressure, body mass index, serum haemoglobin A1c level, serum CRP level, serum lipid levels, PWV or ABI between the placebo- (n = 10) and the fluvastatin-treated patients (n = 12). After 6 months, the PWV and the serum oxidized low-density lipoprotein cholesterol (LDL-C) level increased significantly (from 1969 ± 140 to 2326 ± 190 cm/s and 70.4 ± 13.8 to 91.8 ± 15.5 U/l, respectively) in the placebo-treated patients. However, the fluvastatin group had a significantly reduced PWV (from 1991 ± 162 to 1709 ± 134 cm/s), oxidized LDL-C serum levels (from 89.0 ± 9.6 to 73.0 ± 5.8 U/l) and CRP serum levels (from 0.97 ± 0.32 to 0.26 ± 0.16 mg/dl) compared with those in the placebo group. Conclusions. Long-term administration of fluvastatin prevents further worsening of arterial biomechanics in haemodialysis patients with type 2 diabetes mellitus, even in the presence of serum lipid levels in the normal range.

AB - Background. Arterial stiffness assessed by pulse wave velocity (PWV) predicts all-cause and cardiovascular mortality in diabetic patients with end-stage renal disease. We studied the preventive effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on arterial PWV values in this population. Methods. Twenty-two patients with normal serum lipid levels received fluvastatin (20 mg/day p.o.) or a placebo for 6 months. Their serum lipid levels, serum levels of C-reactive protein (CRP), arterial PWV, and ankle branchial indexes (ABI) were determined before, and 3 and 6 months after taking the medication to evaluate arterial stiffness. Results. At the beginning of the follow-up, there were no differences in age, blood pressure, body mass index, serum haemoglobin A1c level, serum CRP level, serum lipid levels, PWV or ABI between the placebo- (n = 10) and the fluvastatin-treated patients (n = 12). After 6 months, the PWV and the serum oxidized low-density lipoprotein cholesterol (LDL-C) level increased significantly (from 1969 ± 140 to 2326 ± 190 cm/s and 70.4 ± 13.8 to 91.8 ± 15.5 U/l, respectively) in the placebo-treated patients. However, the fluvastatin group had a significantly reduced PWV (from 1991 ± 162 to 1709 ± 134 cm/s), oxidized LDL-C serum levels (from 89.0 ± 9.6 to 73.0 ± 5.8 U/l) and CRP serum levels (from 0.97 ± 0.32 to 0.26 ± 0.16 mg/dl) compared with those in the placebo group. Conclusions. Long-term administration of fluvastatin prevents further worsening of arterial biomechanics in haemodialysis patients with type 2 diabetes mellitus, even in the presence of serum lipid levels in the normal range.

KW - Ankle brachial index

KW - End-stage renal disease

KW - HMG-CoA reductase inhibitor

KW - Oxidized low-density lipoprotein

KW - Pulse wave velocity

UR - http://www.scopus.com/inward/record.url?scp=0035993292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035993292&partnerID=8YFLogxK

M3 - Article

C2 - 12147804

AN - SCOPUS:0035993292

VL - 17

SP - 1513

EP - 1517

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 8

ER -